Selected publications

SELECTED PUBLICATIONS AND PRESENTATIONS Linda M. Thurmond, PhD, ImmunoDynamics Consulting Inc. [email protected] (919) 614-7855 Domanico, P and LM Thurmond. 2008. In Vitro and In Vivo Validation. Cambridge Healthtech Institute Conference, Accelerating Proof-of-Concept, Boston, MA, 8 Oct 2008. Robertson, MJ, Kirkwood, J, Logan, T, Koch, KM, Kathman, S, Pandite, LN, Kirby, LC, Bell, WN, Thurmond, LM, Weisenbach, J, Blair, H, Dar, MM (2008). A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer. Clin. Cancer Res. 14: 3462-3469. Robertson, MJ, JW Mier, T Logan, M Atkins, H Koon, KM Koch, S Kathman, LN Pandite, C Oei, LC Kirby, RC Jewell, WN Bell, LM Thurmond, J Weisenbach, S Roberts, MM Dar (2006). Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer. Clin. Cancer Res., 12: 4265-73. Walsh, J, MJ Reese, LM Thurmond, JR Ravitch. 2005. Post-marketing studies to address the mechanisms of abacavir hypersensitivity reactions: the potential role of drug metabolism. 13th North American ISSX Meeting/20th ISSX Meeting, Maui, HI, 23-27 Oct 2005. King D, S Tompkins, A Waters, PE Easterbrook, LM Thurmond, DE Thorborn, F Raffi, DM Kemeny, A Vyakarnam (2005). Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in human immunodeficiency virus-infected subjects. J. Allergy Clin. Immunol. 115:1081-7. Thurmond, LM. 2004. Immunogenicity Biomarkers for Biopharmaceuticals: Application of Qualified Immunogenicity Assays to Clinical Development of Biotherapeutics. Immunogenicity Testing for Protein Therapeutics, San Francisco CA, 29 June 2004. Thurmond, LM, JB Stimmel, AC Ingram, CR Ryan, DM Murray, DJ Eberwein, and VC Knick (2003) Pretreatment of adenocarcinoma cells with Navelbine or Taxol produces a significant increase in Ep-CAM expression through a novel mechanism. Cancer Immunol. Immunother. 52:429-37. Ma, J, S Kennedy-Stoskopf, JM Jaynes, LM Thurmond, and WA Tompkins (2002). Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in culture. J. Virol. 76, 9952-61. Hetherington, S, AR Hughes, M Mosteller, D Shortino, KL Baker, W Spreen, K Davies, A Handley, D Dow, ME Fling, M Stocum, C Bowman, LM Thurmond, AD Roses (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122. Thurmond LM, D Thorborn, J Ravitch, C Bazin, E Bouvet, B Hoen, A Lafeuillade, F Raffi, S Matheron, S Hetherington. 2000. Immunohistologic characterization of skin rash observed in patients on abacavir who experience a hypersensitivity reaction. 2nd Int’l Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto Canada, September 2000 Thurmond, LM. 2000. Immunologic Interactions in Drug Hypersensitivity. GlaxoSmithKline Hypersensitivity Training Workshop, HIV and Opportunistic Infections Therapeutic Development Group, Durham NC, February 2000. Thurmond, LM, MJ Reese, RJ Donaldson, and BS Orban (1998) A kinetic enzyme immunoassay for the quantitation of antibodies to a humanized monoclonal antibody in human serum. J. Pharm. Biomed. Analysis 16(8), 1317-1328. Hutchins, JT, FC Kull Jr., J Bynum, VC Knick, LM Thurmond, and P Ray (1995) Improved biodistribution, tumor targeting and reduced immunogenicity in mice with a gamma-4 variant of Campath-1H. Proc.Natl.Acad.Sci. 92, 11980-11984. Thurmond, LM, RV House, and JH Dean (1991) Disturbance in calcium signalling and phosphatidylinositol metabolism in murine lymphocytes exposed to 7,12-dimethylbenz[a]anthracene (DMBA). In Vitro Toxicol. 4, 217-230. Leventhal, BG, HK Kashima, P Mounts, LM Thurmond, S Chapman, S Buckley, and D Wold (1991) A long-term study of lymphoblastoid interferon in recurrent respiratory papillomatosis. New Engl. J. Med. 325, 613-617. House, RV, MJ Pallardy, JB Cornacoff, LM Thurmond, and JH Dean (1989) Suppression of cytolytic function in murine lymphocytes exposed to 1,4-bis[(2-aminoethyl)amino]-5,8-dihydroxy-9,10-anthracenedione) dihydrochloride (AEAD): inhibition of proliferation by cytotoxic T-lymphocyte precursors. Int. J. Immunopharm. 11, 301-308. Thurmond, LM. 1988. Anti-interferon-alpha n1 antibodies in juvenile laryngeal papillomatosis patients. Invited Speaker, Workshop on Problems Contingent to Cytokine Therapy, 1988 International Society for Interferon Research Meeting on Interferons and Cytokines. Kyoto, Japan Thurmond, LM, RV House, LD Lauer, and JH Dean (1988) Suppression of splenic lymphocyte function by 7,12-dimethylbenz[a]anthracene (DMBA) in vitro. Toxicol. Appl. Pharmacol. 93, 369-377. Thurmond, LM and JH Dean (1988) Immunological responses following inhalation exposure to chemical hazards. In: Toxicology of the Lung, edited by DE Gardner, JD Crapo, and EJ Massaro, pp. 375-406. Raven Press, New York. Dean, JH, LM Thurmond, LD Lauer, and RV House (1987) Comparative toxicology and correlative immunotoxicology in rodents. In: Environmental Chemical Exposures and Immune System Integrity, Adv. Mod. Environ. Toxicol. 13, edited by EJ Berger, RD Tardiff, and JA Bellanti, pp. 85-102 Princeton Scientific Publishing, Inc., Princeton New Jersey.

Source: http://www.immunodynamicsconsulting.com/files/SELECTED_PUBLICATIONS2.pdf